Latest Articles

Publication Date
Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer - Targeted Oncology

Phase 3 Trial of T-DXd Initiated in HER2+ Endometrial Cancer Targeted Oncology

Published: Dec. 23, 2025, 2:07 p.m.
Deconvolution of DNA Methylation Data Reveals Cell-Type-Specific Epigenomic Signatures in Endometriosis and Eutopic Endometrium.

Endometriosis (EM) is a debilitating disease involving the growth of endometrial glands and stroma outside the uterus. To further our understanding of epigenomic dysregulation in EM and search for disease …

Published: Dec. 23, 2025, midnight
Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer - Targeted Oncology

Safety and Optimal AE Management of Lenvatinib Plus Pembrolizumab in Endometrial Cancer Targeted Oncology

Published: Dec. 22, 2025, 1:15 p.m.
Endometrial Assembloid Model Reveals Endometrial Gland Development Regulation by Estradiol-Driven WNT7B Suppression.

Adult endometrial glands undergo cyclic regeneration and development during the menstrual cycle. Their secretions are vital for endometrial functions and early pregnancy, yet the mechanisms controlling gland development are not …

Published: Dec. 22, 2025, midnight
Systematic analyses uncover endocrine-disrupting chemical-responsive genes linked to endometriosis.

Endometriosis is a chronic, estrogen-dependent disorder influenced by both genetic and environmental factors, including endocrine-disrupting chemicals (EDCs). This study aimed to identify EDC-responsive genes contributing to endometriosis risk by integrating …

Published: Dec. 22, 2025, midnight
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
EGR1 promotes ferroptosis in endometriosis through transcriptional activation of HMOX1.

Endometriosis (EM) affects approximately 10% of women of reproductive age and remains a prevalent estrogen-dependent gynecological disorder with limited therapeutic efficacy and high recurrence rates. Ferroptosis-an iron-dependent, non-apoptotic form of …

Published: Dec. 19, 2025, midnight
Andrographolide blocked the progression of endometriosis by promoting ferroptosis via inhibiting anabolism of serine.

Ferroptosis is a potential target for the treatment of endometriosis (EMs). The role of andrographolide (AP) in the ferroptosis has gradually attracted attention, but its mechanism of action in endometriosis …

Published: Dec. 18, 2025, midnight
Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.

Endometriosis, which affects approximately 10% of women of reproductive age, is a complex inflammatory disease with significant immune system disturbances caused by an inadequate immune response to retrograde menstruation and …

Published: Dec. 18, 2025, midnight
Dysregulated autophagy in endometriosis: molecular mechanisms, controversies, and clinical implications.

Endometriosis is one of the most common gynecological diseases in women and is still one of the most understudied diseases, affecting the daily lives of patients. Although the exact cause …

Published: Dec. 13, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!